Here's what the data showed: Weight Loss by Dose (48 Weeks) Why this matters: The FDA-approved semaglutide (Wegovy) produced around 1517% weight loss in its pivotal trials
It's worth highlighting, though, that poorly controlled diabetes itself elevates the risk of gastroparesis
Biosimilars and generics could cut costs by 7080%, transforming GLP-1s from elite therapies into public-health tools
That is the test before you invest logic: fewer assumptions, a better conversation with your provider
CrossRef Predicting MASLD in People With HIV Using Anthropometric Measures: A Multicenter Cross-Sectional Study Jihad Slim, Murad Qirem, Paul Bellafiore, Bereket Tewoldemedhin, Tala B Shahin, Kevin Leyden, Ronald Poblete, Sandhya Nagarakanti, Hugo Vargas Open Forum Infectious Diseases .2026;[Epub] CrossRef Current Trends and Perspectives on Obesity and Metabolic Dysfunction-Associated Steatohepatitis in East Asia Soo Lim, Hui Zhou, Wataru Ogawa Journal of Obesity & Metabolic Syndrome .2026

This list compares their: Medication : Primary Use // Frequency // Starting Dose // Maximum Amount Ozempic: Type 2 Diabetes // Once Weekly // 0.25 mg // 2.0 mg Wegovy : Weight Loss // Once Weekly // 0.25 mg // 2.4 mg up to 7.2 mg* T irzepatide(Mounjaro / Zepbound): Diabetes & Weight Loss // Once Weekly // 2.5 mg // 15.0 mg Retatrutide (Phase 3 Trials): Weight Loss (Investigational) // Once Weekly // 2.0 mg // 12.0 mg Effectivness Comparing data from Retatrutide clinical trials shows it to be significantly more effective for weight loss when compared to previous GLP-1 medications